• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    11/4/22 4:16:09 PM ET
    $ANTM
    Medical Specialities
    Health Care
    Get the next $ANTM alert in real time by email
    8-K
    false 0001156039 0001156039 2022-10-26 2022-10-26

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 4, 2022 (October 26, 2022)

     

     

    Elevance Health, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Indiana   001-16751   35-2145715

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    220 Virginia Avenue
    Indianapolis, Indiana 46204
    (Address of principal executive offices) (Zip Code)

    Registrant’s telephone number, including area code: (833) 401-1577

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock   ELV   NYSE

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 8.01

    Other Events.

    The Notes Offering

    On November 4, 2022, Elevance Health, Inc. (the “Company”) closed its sale of $400.0 million aggregate principal amount of its 5.350% Notes due 2025 (the “2025 Notes”), $650.0 million aggregate principal amount of its 5.500% Notes due 2032 (the “2032 Notes”) and $750.0 million aggregate principal amount of its 6.100% Notes due 2052 (the “2052 Notes” and, together with the 2025 Notes and the 2032 Notes, the “Notes”) pursuant to an Underwriting Agreement, dated October 26, 2022 (the “Underwriting Agreement”), among the Company and BofA Securities, Inc. and Deutsche Bank Securities Inc., as representatives of the several underwriters named on Exhibit A thereto (the “Underwriters”). The Notes have been registered under the Securities Act of 1933, as amended (the “Act”) pursuant to a registration statement on Form S-3 (File No. 333-249877) previously filed with the Securities and Exchange Commission under the Act.

    The Company received proceeds of approximately $1,780.2 million from the sale of the Notes after deducting underwriting discounts and its offering expenses. The Company intends to use the net proceeds for working capital and for general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt, and the repurchase of its common stock pursuant to its share repurchase program. The Indenture (as defined below) does not prohibit or limit the incurrence of indebtedness and other liabilities by the Company or its subsidiaries.

    The Notes have been issued pursuant to an Indenture, dated as of November 21, 2017 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”). Interest on the Notes is payable semi-annually in arrears on April 15 and October 15 of each year, commencing April 15, 2023. Each interest payment on the Notes will be made to the persons who are registered holders of such Notes at the close of business on the immediately preceding April 1 or October 1 (whether or not a Business Day), as applicable. Interest, in each case, will be computed on the basis of a 360-day year of twelve 30-day months.

    The Notes may be declared immediately due and payable by the Trustee or the holders of 25% of the principal amount of the Notes of the affected series if an event of default occurs under the Indenture and has not been cured. An event of default generally means that the Company (1) fails to pay the principal or any premium on a Note on its due date, (2) does not pay interest on a Note within 30 days of its due date, (3) remains in breach of any other term of the Indenture for 90 days after its receipt of written notice of such failure or (4) files for bankruptcy or certain other events in bankruptcy, insolvency or reorganization occurs.

    The 2025 Notes will mature on October 15, 2025, the 2032 Notes will mature on October 15, 2032 and the 2052 Notes will mature on October 15, 2052. Prior to (i) with respect to the 2025 Notes, September 15, 2025 (one month prior to the maturity date of such Notes), (ii) with respect to the 2032 Notes, July 15, 2032 (three months prior to the maturity date of such Notes) and (iii) with respect to the 2052 Notes, April 15, 2052 (six months prior to the maturity date of such Notes) (each such date, a “Par Call Date”), the Company may redeem the applicable series of Notes at its option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed discounted to the redemption date (assuming, in the case of the 2025 Notes, the 2032 Notes and the 2052 Notes, that such Notes matured on their applicable Par Call Date), on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate, as defined in the Indenture, plus 15 basis points in the case of the 2025 Notes, 25 basis points in the case of the 2032 Notes and 30 basis points in the case of the 2052 Notes less (b) interest accrued to the redemption date; and (2) 100% of the principal amount of the Notes to be redeemed; plus, in either case, accrued and unpaid interest on the applicable Notes to the redemption date.

    On or after the applicable Par Call Date for the 2025 Notes, the 2032 Notes and the 2052 Notes, the Company may redeem the Notes of the applicable series in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Notes being redeemed, plus accrued and unpaid interest thereon to such redemption date.

    Unless the Company has exercised its right to redeem the Notes in full as described above, upon the occurrence of both (1) a change of control of the Company and (2) a downgrade of a series of the Notes below an investment grade rating by each of Moody’s Investors Services, Inc., S & P Global Ratings and Fitch Ratings, Inc. within a specified period, the Company will be required to make an offer to purchase all of the Notes of such series at a price equal to 101% of the principal amount of such Notes, plus any accrued and unpaid interest to the date of repurchase.


    Certain of the Underwriters and their affiliates are full service financial institutions that have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with the Company and its affiliates, for which they have received, or may in the future receive, customary fees and commissions.

    The foregoing description of the issuance and sale does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is incorporated by reference hereto as Exhibit 1.1, and the Indenture, which is filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 21, 2017.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

    The following exhibits are being filed herewith:

     

    Exhibit
    No.
      

    Exhibit

    1.1    Underwriting Agreement, dated as of October 26, 2022, among Elevance Health, Inc. and BofA Securities, Inc. and Deutsche Bank Securities Inc.
    4.1    Form of the 5.350% Notes due 2025
    4.2    Form of the 5.500% Notes due 2032
    4.3    Form of the 6.100% Notes due 2052
    5.1    Opinion of Hogan Lovells US LLP
    5.2    Opinion of Faegre Drinker Biddle & Reath LLP
    23.1    Consent of Hogan Lovells US LLP (included in the opinion filed as Exhibit 5.1)
    23.2    Consent of Faegre Drinker Biddle & Reath LLP (included in the opinion filed as Exhibit 5.2)
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: November 4, 2022

     

    ELEVANCE HEALTH, INC.
    By:  

    /s/ Kathleen S. Kiefer

    Name:   Kathleen S. Kiefer
    Title:   Corporate Secretary
    Get the next $ANTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANTM

    DatePrice TargetRatingAnalyst
    6/22/2022$607.00 → $533.00Overweight → Equal-Weight
    Morgan Stanley
    6/17/2022$550.00Buy
    Loop Capital
    5/27/2022$577.00 → $596.00Outperform
    Bernstein
    2/7/2022$475.00 → $500.00Buy
    Argus Research
    1/28/2022$561.00 → $518.00Overweight
    Morgan Stanley
    1/27/2022$430.00 → $465.00Market Perform
    SVB Leerink
    12/20/2021$450.00 → $510.00Neutral → Buy
    Mizuho
    12/17/2021$486.00 → $561.00Overweight
    Morgan Stanley
    More analyst ratings

    $ANTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anthem Announces Subsidiary Brands Under Elevance Health

      Changes reflect the company's continued evolution to support whole health As Anthem, Inc. (ANTM) moves closer to rebranding to Elevance Health, Inc. later this month, the company today announced the launch of healthcare services brand Carelon and health plan brand Wellpoint to join the company's family of brands that includes Anthem Blue Cross and Blue Shield. The move will optimize and streamline the company's brand portfolio, reduce complexities, and further underscore its evolution to deliver solutions beyond traditional health insurance, simplify the healthcare experience, and advance health beyond healthcare. "An important part of being a lifetime, trusted health partner is grounded

      6/15/22 10:00:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem, Inc. Aims to Enhance Maternal Health with New Digital-First Solution

      Anthem partners with Happify Health to bring innovative digital health services to areas of women's health including pregnancy, menopause, and more Anthem, Inc. (NYSE:ANTM), a leading health company dedicated to improving lives and communities, will add to its ongoing support of the whole health of women with the addition of a new a digital-first solution in select markets. This program, a collaboration between Anthem – soon to be Elevance Health on June 28 – and Happify Health, bridges the gap between the unique physical and mental health concerns women face. It is part of Anthem's early and consistent support of women throughout the entirety of their maternal health journey with solution

      6/7/22 7:55:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem Announces Appearance at Upcoming Conference

      Anthem, Inc. (NYSE:ANTM) announced today that senior management is scheduled to present at the 38th Annual Bernstein Strategic Decisions Conference in New York City on June 3, at 8:00 a.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a webcast of the presentation by visiting www.antheminc.com and selecting the "Investors" link. Following the presentation, a webcast replay will be available for two weeks. To listen to the live webcast, please visit Anthem's website at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Anthem's most recent filings with the SEC,

      5/26/22 4:05:00 PM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Financials

    Live finance-specific insights

    See more
    • Anthem, Inc. Completes Acquisition of Integra Managed Care

      Anthem, Inc. (NYSE:ANTM) today announced the completion of its acquisition of Integra Managed Care, a Managed Long-Term Care Plan in New York that helps adults with long term care needs and disabilities live safely and independently in their own home. "We're pleased to complete this acquisition and work alongside our new colleagues as we continue to grow our Medicaid business and enhance the healthcare experience for all of our members," said Felicia Norwood, Executive Vice President of Anthem's Government Business Division. "Anthem and Integra's shared commitment to deliver high quality, comprehensive whole-health care across communities throughout New York ensures that our members will c

      5/5/22 7:48:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem Reports First Quarter 2022 Results, Reflecting Strong Momentum Across All Divisions

      First quarter GAAP net income was $7.39 per share, including net negative adjustment items of $0.86 per share. Adjusted net income was $8.25* per share. Operating revenue grew by 18.0% over the prior year quarter to $37.9 billion. Operating gain grew by 13.2% over the prior year quarter to $2.4 billion. Medical enrollment increased by 3.3 million members year-over-year and 1.4 million members sequentially to 46.8 million members. Second quarter 2022 dividend of $1.28 per share declared to shareholders. Anthem, Inc. (NYSE:ANTM) reported first quarter 2022 results reflecting strong financial performance, including double-digit top and bottom line growth. "Our strong momentum a

      4/20/22 6:00:00 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Anthem to Hold Conference Call and Webcast to Discuss First Quarter Results on April 20, 2022

      Anthem, Inc. (NYSE:ANTM) will release first quarter 2022 financial results on April 20, 2022, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 800-813-5525 (Domestic Replay) 312-470-0178 (International) 203-369-3346 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on April 20, 2022 until the end of the day on May 20, 2022. The cal

      4/6/22 4:05:00 PM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    SEC Filings

    See more
    • Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      11/4/22 4:16:09 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 424B3 filed by Anthem Inc.

      424B3 - Elevance Health, Inc. (0001156039) (Filer)

      10/27/22 4:22:42 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form FWP filed by Anthem Inc.

      FWP - Elevance Health, Inc. (0001156039) (Subject)

      10/26/22 5:22:59 PM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Anthem Inc. (Amendment)

      SC 13G/A - Anthem, Inc. (0001156039) (Subject)

      2/9/22 3:24:47 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Anthem, Inc. (0001156039) (Subject)

      2/10/21 10:30:29 AM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Anthem downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Anthem from Overweight to Equal-Weight and set a new price target of $533.00 from $607.00 previously

      6/22/22 7:17:32 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Loop Capital initiated coverage on Anthem with a new price target

      Loop Capital initiated coverage of Anthem with a rating of Buy and set a new price target of $550.00

      6/17/22 7:14:30 AM ET
      $ANTM
      Medical Specialities
      Health Care
    • Bernstein resumed coverage on Anthem with a new price target

      Bernstein resumed coverage of Anthem with a rating of Outperform and set a new price target of $596.00 from $577.00 previously

      5/27/22 7:11:36 AM ET
      $ANTM
      Medical Specialities
      Health Care

    $ANTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Treace Medical Concepts Appoints New Directors

      PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa

      10/4/21 8:00:00 AM ET
      $ANTM
      $TCMD
      $TMCI
      Medical Specialities
      Health Care
      Medical/Dental Instruments
    • David P. Abney, Gail K. Boudreaux Named to Target Corporation's Board of Directors

      MINNEAPOLIS, Aug. 11, 2021 /PRNewswire/ -- Target Corporation (NYSE:TGT) announced today its board of directors elected David P. Abney, former chairman of the board and chief executive officer of United Parcel Service, Inc., and Gail K. Boudreaux, president and chief executive officer of Anthem, Inc., as directors. Mr. Abney's appointment is effective immediately and Ms. Boudreaux's appointment becomes effective September 23, 2021. Mr. Abney, 65, held a series of escalating leadership roles at UPS over his more than 40-year career. He was named CEO in September 2014 and chairman and CEO in February 2016, a role he held until announcing his retirement in June 2020. He remained executive chair

      8/11/21 4:05:00 PM ET
      $ANTM
      $TGT
      Medical Specialities
      Health Care
      Department/Specialty Retail Stores
      Consumer Discretionary
    • Dante Labs Announces Appointment of Healthcare Veteran and GRAIL SVP Mark Morgan to Board Of Directors to Support Genomic and Precision Medicine Scaling in the United States

      CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Mark Morgan as a board member. Mark is the SVP of Market Access for GRAIL, which has developed a highly innovative multi-cancer, early detection blood test. "We are excited to welcome Mark Morgan to the Dante Labs Board," said Dante Labs CEO Andrea Riposati, "Mark is a rockstar in healthcare. His deep experience with health plans, coupled with market access expertise in both biopharma and diagnostics will be invaluable to Dante Labs as we continue to build on our global success and expansion in the United States." Mr. Morgan state

      8/9/21 7:39:23 AM ET
      $AMGN
      $ANTM
      $ILMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities

    $ANTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Todt Blair Williams was granted 3,983 shares, increasing direct ownership by 93% to 8,283 units

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      1/5/23 5:03:57 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 4: Norwood Felicia F covered exercise/tax liability with 1,754 shares, decreasing direct ownership by 6% to 26,684 units

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      1/4/23 4:50:33 PM ET
      $ANTM
      Medical Specialities
      Health Care
    • SEC Form 4: Todt Blair Williams covered exercise/tax liability with 117 shares, decreasing direct ownership by 3% to 4,300 units

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      12/5/22 4:53:39 PM ET
      $ANTM
      Medical Specialities
      Health Care